Hematology Frontier

September 4 marks "World Leukemia Day," an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called "blood cancer," is a complex disease with high treatment costs and the risk of relapse, placing a heavy burden on many families. However, through awareness and action on this day, we aim to break the silence and helplessness, and collectively ignite a beacon of hope for leukemia patients.

To foster interdisciplinary integration in hematology, accelerate the innovation and translation of scientific research, promote high-quality development of the discipline, and contribute to the Healthy China Initiative, the 5th Annual Meeting of Chinese Alliance for Societies of Hematology (CASH) will be held from January 3rd to 5th, 2025, in Tianjin.

From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, bringing together global experts to discuss the latest advancements in hematology. During this prestigious event, Dr. Minghui Duan from Peking Union Medical College Hospital presented his team’s latest findings on myelofibrosis (MF) treatment (Abstract #1002), offering new perspectives for future therapeutic strategies. To provide deeper insights, Hematology Frontier invited Professor Duan for an in-depth discussion on his research.

Minimal residual disease (MRD) is a powerful predictor of relapse in acute myeloid leukemia (AML), yet its accuracy remains a challenge. Some patients who are MRD-positive do not relapse, while others who are MRD-negative still experience disease recurrence. At the 2024 American Society of Hematology (ASH) Annual Meeting, Professor Jerald Radich from Fred Hutchinson Cancer Center provided an in-depth analysis of how mutations, clonal architecture, and disease evolution influence treatment response, resistance, and relapse.To clarify the complex relationship between MRD and clonal dynamics, Hematology Frontier has compiled key insights from this discussion.

From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, where global experts gathered to discuss the latest advancements…

From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting convened in San Diego, bringing together global hematology experts to discuss the latest advancements in…

From December 7 to 10, 2024, the 66th American Society of Hematology (ASH) Annual Meeting took place in San Diego, USA, where leading experts in hematology gathered to discuss the…

On November 14, 2024, the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) and the 40th Anniversary of the China Anti-Cancer Association (CACA) commenced at the Xi’an International Conference Center. Themed “CACA at 40: Carrying Forward and Innovating,” the event brought together medical experts, patient advocates, and leaders from various sectors to advance the fight against cancer.

From January 17 to 19, 2025, the Chinese Society of Clinical Oncology (CSCO) Leukemia, Lymphoma, and Multiple Myeloma Expert Committee Meeting & 2025 CSCO Hematologic Oncology Conference was held in the scenic city of Haikou. This high-profile event brought together leading experts from China and abroad to discuss the latest advances in leukemia, lymphoma, and multiple myeloma, covering both fundamental research and clinical applications. The conference also addressed key challenges in diagnosis and treatment, fostering in-depth discussions among specialists.